|
Audrey Tseng / 曾惠瑾 |
Current Positions
-
Honorary Deputy Chairman of PwC Taiwan
-
Adjunct Professor of National Chengchi University
-
Managing Supervisor of Taiwan Bio-industry Organization
-
Managing Supervisor of Precision Medicine & Molecular Diagnostics Industry Association of Taiwan.
-
Director, Taipei Biotech Association
-
Supervisor of Food Industry Research and Development Institute
-
Supervisor of Medical and Pharmaceutical Industry Technology and Development Centre
-
Member of various review committees for competitions, funding plans, and investment plans, both held by governments and private entities
Education
-
Master of Business Administration, Executive MBA of Fudan University and National Taiwan University
-
Master of Commerce, Department of Accounting, National Chengchi University
Experience
-
PwC Deputy Chairman/ CaTSH Synergies Leader/ Markets Leader/Assurance Leader/ Industry Development Committee Leader/Risk Management Leader/ Research & Development Committee Leader
-
Chairman, Alumni Association for Accounting Department of National Chengchi University
-
Director, Taiwan Accounting Association
Specialties
With over 30 years of experience as a Taiwan-licensed CPA, Audrey’s main clients include leading Taiwanese companies such as Taiwan Stock Exchange, Delta Electronics, Asustek, Foxconn, WPG Holdings and TECO. She specializes in multinational financial and tax planning, M&A, corporate governance, industrial development and business strategies. Audrey has an intimate understanding in pharmaceuticals, biotech, medtech, and innovative hi-tech industries. She has also successfully assisted many biopharma and medtech companies to list in Taiwan, including BIONET, Formosa Laboratories, PharmaEngine, OBI Pharma, Taiwan Lipsome, TWI Pharma, Crown Bioscience, Senhwa Biosciences, Tanvex BioPharma, Lumosa Therapeutics, Foresee Pharmaceutical , EirGenix, Medeon Biodesign, CHC Healthcare Group, Onxy Healthcare, Taiwan Biomaterial and Applied Biocode Corporation, etc. Audrey also has extensive overseas IPO advisory experiences, including Tom.com, Delta Networks, TOT Biopharma’s IPO in Hong Kong and Taiwan Liposome Company’s ADR issuance in the U.S. Recently Audrey has been providing dedicated IPO consulting services for companies intending to register on China A-shares and Sci-Tech Innovation Board.
